Ovoca Bio Plc Logo

Ovoca Bio Plc

ISIN: IE00B4XVDC01 | Ticker: OVXA | LEI: 213800ST2AK5XQ1O5207
Sector: Health CareSub-Industry: Biotechnology
Country: Ireland

About Ovoca Bio Plc

Company Description

Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. In 2018 the Company acquired control of IVIX, a biotechnology company developing Orenetide (BP-101), a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Since the initial acquisition, Ovoca Bio has supported the continued clinical development and commercial planning of Orenetide, which has been submitted for marketing authorisation in Russia and has commenced a Phase II study in a western population with HSDD. In March 2020, Orenetide became a fully owned program of Ovoca Bio.

Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia.

Year founded


Served area

Irland, UK, Russia


17 Pembroke Upper Street, D02 AT22 Dublin 2 – Ireland

Filings & Publications

Sign up and we will give you access!

Insider Trades

Sign up and we will give you access!

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

Euronext Dublin

Stock Index

ISEQ Overall Index

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.